Sun Pharmaceutical Industries Ltd.
- MCAP
- —
- P/E
- —
- P/B
- —
- DIV YLD
- —
- VOLUME
- —
Fundamental snapshot
Latest available consolidated resultsQuarterly results
Consolidated · ₹ crore, except earnings per share
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 14,405.22 | 15,469.07 | 14,559.75 | 15,183.55 |
| Net profit | 3,137.09 | 3,401.09 | 2,723.72 | 2,910.8 |
| EPS (₹) | 13 | 14 | 11.3 | 12.1 |
Reporting periods may lag new filings. Compare the same quarter across years to account for seasonality.
Profit & cash flow
Annual consolidated figures · ₹ crore
Profit and operating cash flow measure different things. Compare them over several years and review working-capital changes.
Shareholding pattern
As of Mar 2026
Ownership percentages are reported snapshots. They do not measure daily FII or DII flows.
Balance sheet
Consolidated · Mar 2026 · ₹ crore
- Total assets
- 1,08,785
- Shareholders’ funds
- 83,570
- Cash & bank balances
- 11,603
Review assets alongside liabilities, debt maturity and cash generation. Compare companies within the same industry.
Financial questions
Answers derived from the reporting periods shown on this page.
What are the latest available quarterly results for Sun Pharmaceutical Industries?
For the quarter ended Jun 2026, the available consolidated data shows sales of ₹15,184 Cr and net profit of ₹2,911 Cr. Compare the same quarter a year earlier to account for seasonality. These are the latest figures in this dataset; check the exchange for subsequent filings.
How much operating cash flow does Sun Pharmaceutical Industries generate?
For the year ended Mar 2026, operating cash flow was ₹12,419 Cr and reported free cash flow was ₹8,810 Cr. Compare cash generation with net profit for the same year and review working-capital movements in the cash flow statement.
What is the shareholding pattern of Sun Pharmaceutical Industries?
The Mar 2026 shareholding snapshot records promoters at 54.48%, foreign institutions at 15.93%, domestic institutions at 21.11%, public & others at 8.48%. This is a dated ownership snapshot, not a record of daily institutional buying or selling.
What is the debt-to-equity ratio of Sun Pharmaceutical Industries?
The debt-to-equity ratio is 0.04x for Mar 2026. Interpret leverage alongside the company's industry, interest costs and ability to generate cash. Financial-sector balance sheets require different comparisons from industrial businesses.
Where can I review financial statements for Sun Pharmaceutical Industries?
The analysis workspace includes quarterly results, profit and loss, balance sheet, cash flow, financial ratios and shareholding history. The public balance-sheet snapshot covers Mar 2026. Sign in to use the detailed analysis tools, and verify unusual items against the original exchange filings.
Related companies
Open company fundamentals for a comparison. Business mix and accounting may differ.
SUNPHARMA options & derivatives
Connect company fundamentals with options positioning.
Reporting notes
Figures shown on this page may contain errors, omissions, or outdated information. Verify financial data and calculations against the company’s original filings before relying on them.